- Health at Bayer
-
Pharmaceuticals
- Treatment Areas
- Innovation & Technologies
- Cell and Gene Therapy
-
Sustainability
- Patient Access Charter
- Leadership Perspective
- Strengthening Healthcare Access
-
Empowering Women, Globally
- Boosting Family Planning Usage through Digital Channels
- Capacity building: Addressing Root Causes through Partnerships
- Impact at Scale: The Challenge Initiative
- Promoting Awareness: World Contraception Day (WCD) & the Your Life Campaign
- Providing Accessible and Affordable Contraceptives
- Enabling Family Planning in Humanitarian Settings
- Fighting Neglected Tropical Diseases
- Moving Non-Communicable Diseases Care Forward
- Ensuring a Sustainable Product Supply
- Delivering Better Cancer Care
- Transparency
- News & Stories
- Personal Health
- Report a Side Effect
- Medical Counterfeits
Tumor Intrinsic Pathways are a treatment paradigm that consider the molecular and cellular features of a tumor to enable the development of tailor-made therapeutic approaches for individual patients that are ultimately more effective. With our research, we are aiming at disrupting the intracellular tumor signaling pathways responsible for the development and survival of cancer.
For example, non-small cell lung cancers (NSCLC) carry a mutation in exon 20 of the epidermal growth factor receptor (EGFR) gene and is associated with poor prognosis. These mutations cannot be addressed with traditional EGFR inhibitors.
Derived from a long-standing alliance with the Broad Institute of MIT and Harvard, we have an early asset which targets this mutation in the EGFR.
The Bayer Research Innovation Centre (BRIC) in Boston-Cambridge, Massachusetts, U.S., is home to the company’s precision molecular oncology laboratory and reflects the investment Bayer is making to advance the future of oncology and science to generate breakthrough solutions to the world’s most complex challenges.